BWM
BIO icon

Baystate Wealth Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Baystate Wealth Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2
Closed -$1K – 1035
2022
Q4 		$1K Buy
+2
New +$807 ﹤0.01% 836

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baystate Wealth Management's BIO Position: Q1 2023 in Review

Baystate Wealth Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2023, closing a stake of 2 shares — an estimated $1K sold.

Baystate Wealth Management first reported a position in BIO in Q4 2022 and held it in 1 quarter. The position peaked at $1K in Q4 2022. 505 funds tracked by Wall St. Rank hold BIO as of Q1 2023.

  • Baystate Wealth Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2023 after selling out during the quarter.
  • Baystate Wealth Management sold 2 Bio-Rad Laboratories Class A shares in Q1 2023, an estimated $1K.
  • Baystate Wealth Management first reported a position in Bio-Rad Laboratories Class A in Q4 2022 and held it in 1 quarter.
  • Baystate Wealth Management's Bio-Rad Laboratories Class A position peaked at $1K in Q4 2022.
  • 505 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2023.

Based on Baystate Wealth Management's 13F filing for Q1 2023, filed 25 Apr 2023.